Global Infant Formula Ingredients Market Trends and Insights
Rising Parental Awareness of Infant Nutrition
Parents' growing understanding of nutrition and increased access to digital health platforms are driving significant changes in consumer behavior, particularly in their demand for detailed transparency in ingredient formulations and nutrient absorption data. Access to evidence-based parenting information has changed formula purchasing decisions in the infant formula ingredients market. Parents are examining labels more closely and seeking ingredients supported by nutritional and clinical evidence. This behavior increases demand for validated components across both premium and mid-tier products. Formula manufacturers must therefore secure reliable access to clinical-grade bioactive ingredients to maintain product specifications. That requirement can place pressure on manufacturers that lack long-term supply arrangements. It also supports the position of suppliers with documented safety and application capabilities.Demand for Functional and Specialty Ingredients
The infant formula ingredients market is shifting toward products designed to more closely reflect selected functions of breast milk. More than 12 HMO structures are commercially available in 2026, compared with 2-3 a decade earlier, allowing manufacturers to develop multi-HMO blends. DSM-Firmenich and Novonesis are pairing HMOs with selected probiotic strains to support synbiotic positioning. A 2025 randomized trial found that a partially hydrolyzed whey formula containing 6 manufactured HMOs and 2 probiotic strains was safe, well tolerated, and associated with improved gut health measures. These findings give formula brands a documented basis for differentiation above conventional probiotic-only products. The wider availability of such ingredient systems is raising the functional standard expected in the premium segment.Intensifying Advocacy for Breastfeeding as the Optimal Choice
The World Health Assembly adopted a May 2025 resolution that allows member states to request WHO support for regulating digital marketing of breast-milk substitutes. The measure covers social media, influencer activity, and targeted online advertising. Restrictions in these channels can make it more difficult for formula brands to reach first-time parents, particularly in emerging markets. Higher customer acquisition costs can affect the growth of premium and specialty formula products. Ingredient suppliers are indirectly exposed when their customers depend heavily on digital brand building. The infant formula ingredients market must therefore account for marketing restrictions alongside product and safety regulations.Other drivers and restraints analyzed in the report include:
- Government-Funded Fortification Mandates
- Commercialization of Precision-Fermented HMOs
- Food Allergy and Intolerance Prevalence
Segment Analysis
Carbohydrates represented the largest market segment, accounting for a 39.68% share in 2025, primarily due to sustained lactose demand from traditional formula manufacturers. The prebiotics and probiotics segment is expected to register a CAGR of 8.16% through 2031. Within the protein segment, precision fermentation facilitates the production of human casein micelles, offering superior digestibility and nutrient absorption relative to bovine proteins. Growth in the vitamins and minerals segment is reinforced by government fortification mandates, especially in emerging markets where regulations targeting micronutrient deficiencies necessitate enhanced supplementation.Food Standards Australia New Zealand approved MFGM-WPC as a nutritive substance in infant formula in 2025. Proteins, vitamins, minerals, and HMOs complete the major ingredient groups. Lactoferrin and bioactive whey fractions support clinically differentiated products, while Glanbia Nutrition identifies early-life nutrition as an application area. HMOs are smaller by volume but are becoming more widely available as commercial options expand. Nucleotides, taurine, and structured lipids support nutritional completeness and product differentiation.
Cow milk led the source segment with a 67.46% share in 2025 because it has broad supply infrastructure, cost efficiency, and regulatory acceptance. Goat milk is the fastest-growing source, at an 8.11% CAGR through 2031. Its A2-dominant beta-casein profile and smaller fat globules support its use for infants with mild digestive sensitivity. Soy and protein hydrolysates are used in medically indicated formulations. ESPGHAN’s 2025 public consultation on biotics in infant and follow-on formulas illustrates the continuing clinical focus on product composition.
Cow milk remains central to volume supply, but its value profile is changing as manufacturers add bioactive components. Commodity fractions face margin pressure when customers seek specialized nutrition claims. Goat whey protein concentrates and demineralized whey powder are important inputs for goat milk formulas. Species segregation and composition validation can support premium pricing for suppliers that maintain consistent specifications. The infant formula ingredients industry is therefore using source selection as both a nutritional and commercial choice.
Complete Report Scope:
- By Ingredient
- Carbohydrates
- Fats and Oils
- Proteins
- Vitamins and Minerals
- Prebiotics and Probiotics
- Human Milk Oligosaccharides (HMOs)
- Others
- By Source
- Cow Milk
- Goat Milk
- Soy
- Protein Hydrolysates
- Others
- By Form
- Powder
- Liquid and Semi-Liquid
- By Certification/Nature
- Conventional
- Organic
- By Application
- Standard Infant Formula (Stage 1)
- Follow-On Formula (Stage 2)
- Growing-Up Milk (Stage 3)
- Specialty Formula
- By Geography
- North America
- United States
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Netherlands
- Sweden
- Poland
- Belgium
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Vietnam
- Indonesia
- Thailand
- Singapore
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Chile
- Peru
- Colombia
- Rest of South America
- Middle East and Africa
- United Arab Emirates
- Saudi Arabia
- South Africa
- Nigeria
- Egypt
- Morocco
- Turkey
- Rest of Middle East and Africa
- North America
Geography Analysis
Asia-Pacific accounted for 55.33% of total market value in 2025 and is forecast to grow at an 8.34% CAGR through 2031. China remains the largest country-level opportunity in the region, supported by its GB standards framework. India is gaining importance after approvals for DSM-Firmenich GLYCARE 2'-FL and Novonesis MyOli 5HMOMIX broadened access to commercially produced HMOs. DSM-Firmenich reported approval for GLYCARE 2'-FL in India during 2025. Thailand approved FrieslandCampina Ingredients’ Vivinal MFGM for infant formula use in February 2025.North America and Europe are the second- and third-largest geographic blocks. North American demand is shaped by premium organic, specialty, and hypoallergenic products. The FDA’s Operation. Europe has a closely updated regulatory framework for infant formula and specialized formulations. Regulation EU 2025/2017 updated technical requirements for certain protein hydrolysate formulas.
South America, the Middle East, and Africa are smaller segments in the infant formula ingredients market but offer longer-term potential. Brazil benefits from urbanization and demand for premium formula products, while the Middle East and Africa are seeing rising formula use alongside urban growth and expanding hospital births. These markets remain import dependent, which increases exposure to supply disruption and currency movements. The UAE and Saudi Arabia are developing as premium formula distribution hubs with retail and cold-chain infrastructure that can support bioactive-enriched products.
The United States and Canada show increased consumer demand for hypoallergenic, organic, and specialty formulas due to growing parental awareness of food sensitivities and functional nutrition. Ingredient manufacturers are developing plant-based proteins, non-GMO sources, and bioactive components to address these requirements. Europe maintains regulatory oversight through EFSA's assessment procedures for novel ingredients, with human-identical milk oligosaccharides receiving multiple approvals in 2024. The region's emphasis on sustainability and clean label formulations increases demand for organic and precision-fermented ingredients.
Latin America shows growth potential, driven by improving birth rates in Brazil and Mexico, and increasing urbanization that enhances access to modern retail and healthcare. Government nutrition programs and public-private partnerships improve early-life nutrition awareness, benefiting formula manufacturers. The market is moving toward fortified formulas with functional proteins, essential fatty acids, and prebiotics to address micronutrient deficiencies and gut health. The Middle East and Africa market continues to develop, supported by rising incomes, urbanization, and women's workforce participation, resulting in increased demand for infant nutrition products.
List of Companies Covered in this Report:
- FrieslandCampina Ingredients
- Fonterra Co-operative Group Limited
- Arla Foods amba
- Glanbia plc
- DSM-Firmenich
- BASF SE
- Kerry Group plc
- Ingredia SA
- Carbery Group
- Novonesis
- SudzuckerGroup (BENEO)
- Kirin Holdings Company
- Synlait Milk Ltd
- Hilmar Ingredients
- DuPont Nutrition & Health
- Agropur Cooperative
- Vitablend Nederland B.V.
- Kyowa Hakko Europe GmbH
- BioGaia AB
- Jennewein Biotechnologie GmbH
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- FrieslandCampina Ingredients
- Fonterra Co-operative Group Limited
- Arla Foods amba
- Glanbia plc
- DSM-Firmenich
- BASF SE
- Kerry Group plc
- Ingredia SA
- Carbery Group
- Novonesis
- SudzuckerGroup (BENEO)
- Kirin Holdings Company
- Synlait Milk Ltd
- Hilmar Ingredients
- DuPont Nutrition & Health
- Agropur Cooperative
- Vitablend Nederland B.V.
- Kyowa Hakko Europe GmbH
- BioGaia AB
- Jennewein Biotechnologie GmbH

